Melatonin for Neonatal Hypoxic-Ischemic Encephalopathy
Trial Summary
What is the purpose of this trial?
Hypoxic-Ischemic Encephalopathy (HIE) occurs in 20 per 1000 births. Only 47% of neonates treated with the state of the art therapy (induced systemic hypothermia) have normal outcomes. Therefore, other promising therapies that potentially work in synergy with hypothermia to improve neurologic outcomes need to be tested. One potential agent is melatonin. Melatonin is a naturally occurring substance produced mainly from the pineal gland. Melatonin is widely known for its role in regulating the circadian rhythm, but it has many other effects that may benefit infants with HI injury. Melatonin serves as a free radical scavenger, decreases inflammatory cytokines, and stimulates anti-oxidant enzymes. Therefore, melatonin may interrupt several key components in the pathophysiology of HIE, in turn minimizing cell death and improving outcomes. The research study will evaluate the neuroprotective properties and appropriate dose of Melatonin to give to infants undergoing therapeutic hypothermia for hypoxic ischemic encephalopathy.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the drug melatonin for treating neonatal hypoxic-ischemic encephalopathy?
Research shows that melatonin has neuroprotective properties, such as reducing inflammation and preventing cell death, which can help protect newborn brains from damage caused by lack of oxygen. Studies in animals and some early human trials suggest melatonin is safe and may improve outcomes for infants with this condition.12345
Is melatonin safe for use in humans, particularly for neonatal brain protection?
How is the drug melatonin unique in treating neonatal hypoxic-ischemic encephalopathy?
Melatonin is unique because it can cross all physiological barriers to reach subcellular compartments, offering neuroprotection through its antioxidant, anti-apoptotic (preventing cell death), and anti-inflammatory actions. It is considered safe and effective, but more large-scale human trials are needed to confirm its benefits in treating neonatal hypoxic-ischemic encephalopathy.125810
Research Team
Michael Weiss
Principal Investigator
University of Florida
Eligibility Criteria
This trial is for newborns over 36 weeks gestation with Hypoxic-Ischemic Encephalopathy (HIE). They must have had an acute event at birth, show signs of brain dysfunction early on, and meet specific blood criteria. Infants already receiving cooling therapy within 6 hours of birth are eligible. Those with suspected meningitis, metabolic disorders, severe hypoglycemia, or significant congenital issues cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive melatonin in a dose-escalation study alongside therapeutic hypothermia
Follow-up
Participants are monitored for safety and effectiveness after treatment, including developmental follow-up at 18-22 months
Long-term safety and efficacy assessment
Evaluation of long-term safety and potential efficacy via developmental follow-up and MRI
Treatment Details
Interventions
- Magnetic Resonance Imaging
- Melatonin
- Neurological Outcome Assessment
- Pharmacokinetics
Melatonin is already approved in European Union, United States for the following indications:
- Insomnia in adults aged 55 and over
- Sleep disorders in children with autism spectrum disorder
- Insomnia in children and adolescents aged 2-18 with autism spectrum disorder
- Sleep disorders in children with autism spectrum disorder
- Insomnia in adults
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
Thrasher Research Fund
Collaborator